← Issue №17/ week of Oct 25, 2026/Colorectal

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal rct · n=52 · Oct 23, 2026 · Nature Medicine · IF 52.5

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.

New therapybasic sciencetranslationalbiomarker
Clinical takeawayNo clinical action yet: this is a phase 1/2 trial evaluating a novel T cell agonist in ICB-resistant solid tumors. Further phase 2 data are needed before considering clinical use.
What it foundInvikafusp alfa achieved a 14.8% overall objective response rate (4/27) at optimal biological doses (0.08 and 0.12 mg/kg) in ICB-resistant solid tumors, including partial responses in MSS CRC and PD-L1-negative NSCLC.
ContextThis study introduces a first-in-class bispecific T cell agonist targeting Vβ6/Vβ10 subsets, showing preliminary efficacy in ICB-resistant tumors, a population with limited treatment options.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Sullivan RJ … Gulley JL · Nature Medicine · IF 52.5 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues